Hydrofarm Group (HYFM) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
16 Jan, 2026Executive summary
Net sales declined 18.8% year-over-year to $44.0 million in Q3 2024, primarily due to industry oversupply, retail closures, and pricing pressures, but the company remains on track to meet full-year guidance.
Gross profit margin improved to 19.4% from 6.1% year-over-year, driven by a higher mix of proprietary brands, lower restructuring costs, and effective cost-saving actions.
Net loss narrowed to $13.1 million ($0.29 per share) from $19.9 million ($0.44 per share) in the prior year, reflecting higher gross profit and lower SG&A expenses.
Continued diversification of revenue sources, with increased international and non-cannabis sales, and ongoing investment in proprietary brands.
Announced CEO transition effective January 2025, with the current CFO set to become CEO.
Financial highlights
Q3 2024 net sales were $44.0 million, down 18.8% year-over-year; nine-month net sales were $153.0 million, down 14.7% year-over-year.
Gross profit was $8.5 million (19.4% margin), up from $3.3 million (6.1%) last year; adjusted gross profit was $10.7 million (24.3%), up 130 basis points year-over-year.
SG&A expense was $17.6 million, down from $19.5 million last year; adjusted SG&A was $10.7 million, an 11% reduction year-over-year.
Net loss for Q3 2024 was $13.1 million, improved from $19.9 million year-over-year; nine-month net loss was $49.2 million, nearly flat versus prior year.
Cash balance at quarter-end was $24.4 million, with $128 million in total debt and $41 million in total liquidity.
Outlook and guidance
Reaffirmed full-year 2024 guidance for net sales, adjusted EBITDA, and positive free cash flow.
Net sales expected to decline in the low- to high-teens percent range year-over-year, tracking mid-range.
Capital expenditures for 2024 expected to be $2.5–$3.5 million, lowered from prior guidance.
Management expects annual cost savings of over $2.0 million from restructuring and asset sale actions.
Confident in long-term business potential and positioned for growth when industry demand returns.
Latest events from Hydrofarm Group
- Net sales fell 32.7% and a major impairment drove a $242M net loss amid ongoing restructuring.HYFM
Q4 202527 Mar 2026 - Sales dropped 13% and net loss widened, but positive adjusted EBITDA and outlook reaffirmed.HYFM
Q2 20242 Feb 2026 - Sales and profit fell in 2024, but cost cuts and brand mix support margin and cash flow gains in 2025.HYFM
Q4 202424 Dec 2025 - Shelf registration enables up to $50M in securities for growth and strategic flexibility.HYFM
Registration Filing16 Dec 2025 - Director elections, executive pay, and auditor ratification headline the 2025 annual meeting.HYFM
Proxy Filing1 Dec 2025 - Proxy statement covers annual meeting proposals and confirms no major capital changes.HYFM
Proxy Filing1 Dec 2025 - Annual proxy statement details routine voting matters for shareholders.HYFM
Proxy Filing1 Dec 2025 - Sales and margins fell 25% as industry headwinds and restructuring drove guidance withdrawal.HYFM
Q1 202526 Nov 2025 - Sales and margins fell, but restructuring and cost cuts drove improved cash flow and outlook.HYFM
Q2 202523 Nov 2025